Molecular Pathology and Novel Therapies for Lymphoma
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 20 August 2025 | Viewed by 1156
Special Issue Editor
Special Issue Information
Dear Colleagues,
Lymphoproliferative disorders comprise a wide variety of histopathological and clinical entities , mostly treated with chemotherapy for many years. The emergence of small-molecule targeted therapies, antibody–drug conjugates, chimeric antigen receptor T cells (CAR-T), and bispecific T-cell engagers (BITEs) is profoundly modifying the therapeutic approach in this field. However, there is still a gap in understanding the physiopathology of these disorders, determining a lack of effective therapeutic agents.
With this Special Issue, we aim to explore the current knowledge of the molecular pathways and mechanisms of Hodgkin and non-Hodgkin tumorigenesis, covering advances in basic and preclinical research, and proposing relevant and novel therapeutic strategies.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Pathology, cell metabolism, and biomarkers in lymphoma.
- New therapeutic approaches and drug delivery in lymphoma.
- Genetic susceptibility and genomic instability in lymphoma.
- Interaction between tumor cells and the microenvironment in lymphoma.
Dr. Fulvio Massaro
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Hodgkin lymphoma
- non-Hodgkin lymphoma
- hematopathology
- biomarker
- new therapeutic approaches
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
